An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Phase of Trial: Phase III
Latest Information Update: 05 May 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 20 Jun 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Interim results presented at The International Liver Congress™ 2016
- 15 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.